新型コロナウイルス感染症(COVID-19)が世界的なパンデミックとして出現した際、世界は前例のないスピードでワクチンと治療薬の開発・供給に尽力しました。この偉業は何百万もの命を救い、世界的な科学協力の力を証明しました。しかし、SARS-CoV-2ウイルスは進化を続けており、パンデミックを引き起こす可能性のある他のコロナウイルスも依然として懸念材料となっています。

In a new perspective published in the Journal of Medicinal Chemistry, industry experts share how these technologies are reshaping drug discovery and opening doors to treat diseases once thought undruggable. We sat down with two co-authors of the paper — Steven Jerome, Executive Director at Schrödinger and Paraskevi Gkeka, Principal Scientist at Sanofi — to explore how the age of trial-and-error is giving way to a smarter, more computationally-driven approach to drug discovery.
When COVID-19 emerged as a global pandemic, the world mobilized to deliver vaccines and treatments at unprecedented speed. This massive achievement saved millions of lives and demonstrated the power of global scientific collaboration. However, SARS-CoV-2 continues to evolve, and other coronaviruses with pandemic potential remain a concern.
Sign up to receive quarterly updates with the latest from Extrapolations.